GDS Wealth Management Increases Stake in Natera, Inc. $NTRA

GDS Wealth Management grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 11.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,117 shares of the medical research company’s stock after purchasing an additional 7,177 shares during the quarter. GDS Wealth Management’s holdings in Natera were worth $11,609,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Main Management ETF Advisors LLC increased its stake in shares of Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares during the period. Yousif Capital Management LLC raised its position in Natera by 4.5% in the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after acquiring an additional 72 shares in the last quarter. Gries Financial LLC grew its position in Natera by 4.0% during the third quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after buying an additional 74 shares during the period. Blue Trust Inc. raised its holdings in Natera by 23.1% during the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after purchasing an additional 81 shares during the last quarter. Finally, Earned Wealth Advisors LLC lifted its holdings in shares of Natera by 4.7% in the third quarter. Earned Wealth Advisors LLC now owns 1,952 shares of the medical research company’s stock valued at $314,000 after purchasing an additional 88 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Natera Stock Performance

NASDAQ NTRA opened at $241.58 on Friday. The stock has a market capitalization of $33.42 billion, a P/E ratio of -105.49 and a beta of 1.62. The business’s fifty day moving average is $234.18 and its two-hundred day moving average is $191.40. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the completion of the sale, the chief executive officer owned 144,816 shares in the company, valued at approximately $28,957,407.36. This represents a 52.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of Natera stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the completion of the transaction, the director directly owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 514,562 shares of company stock worth $114,292,421. Insiders own 5.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Piper Sandler lifted their target price on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Stephens lifted their price objective on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. UBS Group increased their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, Barclays boosted their price objective on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.